Intas Pharma Signs Agreement for Needle-Free Injection Technology

Intas Pharmaceuticals has entered into an agreement with Integrimedical to introduce a needle-free injection system for IVF and gynaecology treatments in India. Through this partnership, Intas Pharma will become the only company in the country to offer this advanced treatment method. The company stated that this initiative is not just about introducing a new technology, but also about providing meaningful relief and improved comfort to lakhs of patients.

Speaking on the occasion, Intas Pharma Executive Vice President Durga P. Satapathy said that their goal is to bring simpler, safer, and more dignified treatment methods to IVF and gynaecology care. He noted that the IVF market in India is witnessing rapid growth, with around 3 to 5 lakh IVF cycles currently performed every year, a figure expected to rise to 5 to 6 lakh cycles by 2027.

With this rapid expansion, the implementation of the needle-free injection system is expected to benefit a large number of patients by enabling pain-free treatment. The new NFIS (Needle Free Injection System) technology uses a high-pressure jet to deliver medication through a micro-orifice in the skin, allowing the drug to enter the body without the use of needles, thereby eliminating needle-related pain and anxiety.